Martin Bexon, MD

Dr. Martin Bexon serves as the Chief Medical Officer for Curtana Pharmaceuticals, bringing over 20 years of diverse pharmaceutical industry experience across the United Kingdom, Switzerland, and the United States. A UK- and NZ-trained physician, Dr. Bexon possesses a highly specialized background in strategic and practical clinical development, spanning from early-phase to late-stage trials. His extensive leadership experience includes serving as a Chief Medical Officer with oversight of regulatory affairs, pharmacovigilance, and pharmacometrics, as well as acting as the medical lead for the BioNTech COVID-19 vaccine program.

Dr. Bexon has a proven track record of designing and implementing global clinical programs that have led to the registration and launch of multiple therapies in the US, EU, and Japan. His therapeutic expertise is particularly deep in solid tumor oncology—including glioblastoma (GBM)—as well as neurology, immunology, and pediatrics. Expert in KOL management and the author of numerous scientific publications, he is a member of the European Society for Medical Oncology (ESMO) and holds an MBBS from the University of Newcastle upon Tyne Medical School.